Answers
- Biosimilars
- Methotrexate
- Time
- Presenting problem
- Ultrasound guidance
- International Classification of Diseases
- Current Procedural Terminology
- Trigger points
- Osteoporosis
- Osteoarthritis
From the College | Issue: December 2019 |
Answers
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
Musculoskeletal (MSK) ultrasound is a valuable imaging modality for the practicing rheumatologist and provides an efficient tool with high diagnostic value in the evaluation of patients with musculoskeletal complaints. The use of MSK ultrasound has evolved in the U.S. due to the emergence of less-expensive, portable ultrasound units, which provide high-quality gray-scale and power Doppler…
As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…
ATLANTA—Point-of-care ultrasound education mainly has occurred at the undergraduate level at U.S. medical schools, but rheumatology fellowship training programs are rapidly catching up and integrating it into their curricula, according to two program directors who reviewed the state of rheumatology ultrasound education, including potential barriers to its implementation, on Nov. 12 at the 2019 ACR/ARP…